Role of LncRNA-AF085935, IL-10 and IL-17 in Rheumatoid Arthritis Patients With Chronic Hepatitis C

Overview

Journal J Clin Med Res

Specialty General Medicine

Date 2017 Apr 11

PMID 28392862

Citations 7

Authors

Dina Sabry

Azza Elamir

Rania Hosny Mahmoud

Ahmed Ali Abdelaziz

Wael Fathy

Affiliations

Soon will be listed here.

Abstract

Background: The current study aimed at testing the effect of corticosteroid therapy on serum levels of interleukin-10 (IL-10) and IL-17 as well as lncRNA-AF085935 in patients of rheumatoid arthritis (RA) associated with hepatitis C virus (HCV) and evaluating the usefulness of using these parameters to predict the therapeutic efficacy of steroids in these patients.

Methods: Thirty healthy control subjects and 65 chronic HCV patients with RA were included in our study. Patients were subjected to clinical examination, abdominal ultrasound, and liver biopsy and received 6-methyl-prednisolone (PDN) 16 mg/day for 48 weeks. Blood samples were collected from all subjects and serum was separated to assess IL-10 and IL-17 by ELISA and HCV RNA and lncRNA-AF085935 by qRT-PCR.

Results: Our study revealed that there were significant increases in serum levels of IL-10, IL-17 and lncRNA-AF085935 in RA patients associated with HCV compared with healthy control subjects. Also there were significant increases in serum levels of IL-10 and HCV RNA and a significant decrease in serum level of IL-17 in patients after corticosteroid therapy, while lncRNA-AF085935 is not significantly changed.

Conclusion: LncRNA-AF085935 might be a useful candidate biomarker for the early detection of RA associated with HCV, providing potential new strategies for early screening and therapy of these patients. IL-17 is a non-invasive prognostic marker to predict the efficacy of corticosteroid therapy in RA patients associated with chronic hepatitis C.

Citing Articles

Long non-coding RNA XIST binding to let-7c-5p contributes to rheumatoid arthritis through its effects on proliferation and differentiation of osteoblasts via regulation of STAT3.

Wang Z, Xiu D, Jiang J, Liu G J Clin Lab Anal. 2020; 34(11):e23496.

PMID: 32881056 PMC: 7676202. DOI: 10.1002/jcla.23496.

LncRNAs in HCV Infection and HCV-Related Liver Disease.

Unfried J, Fortes P Int J Mol Sci. 2020; 21(6).

PMID: 32214045 PMC: 7139329. DOI: 10.3390/ijms21062255.

IL‑1β increases the expression of inflammatory factors in synovial fluid‑derived fibroblast‑like synoviocytes via activation of the NF‑κB‑mediated ERK‑STAT1 signaling pathway.

Yang J, Wang J, Liang X, Zhao H, Lu J, Ma Q Mol Med Rep. 2019; 20(6):4993-5001.

PMID: 31638264 PMC: 6854543. DOI: 10.3892/mmr.2019.10759.

The effects of long non-coding ribonucleic acids on various cellular components in rheumatoid arthritis.

Fang Y, Tu J, Han D, Guo Y, Hong W, Wei W Rheumatology (Oxford). 2019; 59(1):46-56.

PMID: 31605483 PMC: 6909907. DOI: 10.1093/rheumatology/kez472.

(5R)-5-Hydroxytriptolide (LLDT-8) induces substantial epigenetic mediated immune response network changes in fibroblast-like synoviocytes from rheumatoid arthritis patients.

Guo S, Liu J, Jiang T, Lee D, Wang R, Zhou X Sci Rep. 2019; 9(1):11155.

PMID: 31371761 PMC: 6671973. DOI: 10.1038/s41598-019-47411-1.

References

Peek E, Richards D, Faith A, Lavender P, Lee T, Corrigan C . Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists. Am J Respir Cell Mol Biol. 2005; 33(1):105-11. DOI: 10.1165/rcmb.2005-0100OC. View

Sterling R, Bralow S . Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006; 8(1):53-9. DOI: 10.1007/s11894-006-0064-y. View

Romero Gutierrez M, Del Campo Terron S, Moreno Zamora A, Sanchez Ruano J, Artaza Varasa T, Barcena Marugan R . Does low-dose prolonged steroid therapy affect the natural history of chronic hepatitis C?. J Med Virol. 2014; 86(5):758-64. DOI: 10.1002/jmv.23889. View

Garf A, El Zorkany B, Gheith R, Sheba H, Abdel Moneim G, El Garf K . Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward. Rheumatol Int. 2011; 32(9):2691-5. DOI: 10.1007/s00296-011-2014-8. View

Cush J, Splawski J, Thomas R, McFarlin J, Schulze-Koops H, Davis L . Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1):96-104. DOI: 10.1002/art.1780380115. View

Pryor B, Bologna S, Kahl L . Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996; 39(9):1475-82. DOI: 10.1002/art.1780390906. View

Lasarte J, Garcia-Granero M, Lopez A, Casares N, Garcia N, Civeira M . Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology. 1998; 28(3):815-22. DOI: 10.1002/hep.510280332. View

Louten J, Boniface K, De Waal Malefyt R . Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009; 123(5):1004-11. DOI: 10.1016/j.jaci.2009.04.003. View

Majithia V, Geraci S . Rheumatoid arthritis: diagnosis and management. Am J Med. 2007; 120(11):936-9. DOI: 10.1016/j.amjmed.2007.04.005. View

10.

Sher A, Gazzinelli R, Oswald I, Clerici M, Kullberg M, Pearce E . Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev. 1992; 127:183-204. DOI: 10.1111/j.1600-065x.1992.tb01414.x. View

11.

Straub R, Cutolo M . Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007; 56(2):399-408. DOI: 10.1002/art.22368. View

12.

Bogunia-Kubik K, Swierkot J, Malak A, Wysoczanska B, Nowak B, Bialowas K . IL-17A, IL-17F and IL-23R Gene Polymorphisms in Polish Patients with Rheumatoid Arthritis. Arch Immunol Ther Exp (Warsz). 2014; 63(3):215-21. PMC: 4429134. DOI: 10.1007/s00005-014-0319-5. View

13.

Gramenzi A, Andreone P, Loggi E, Foschi F, Cursaro C, Margotti M . Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat. 2005; 12(5):525-30. DOI: 10.1111/j.1365-2893.2005.00634.x. View

14.

Sacks J, Helmick C, Langmaid G . Deaths from arthritis and other rheumatic conditions, United States, 1979-1998. J Rheumatol. 2004; 31(9):1823-8. View

15.

Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V . Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore). 2000; 79(1):47-56. DOI: 10.1097/00005792-200001000-00005. View

16.

Barrat F, Cua D, Boonstra A, Richards D, Crain C, Savelkoul H . In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002; 195(5):603-16. PMC: 2193760. DOI: 10.1084/jem.20011629. View

17.

Alten R . Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis. Expert Rev Clin Immunol. 2012; 8(2):123-33. DOI: 10.1586/eci.11.95. View

18.

Huang W, Na L, Fidel P, Schwarzenberger P . Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis. 2004; 190(3):624-31. DOI: 10.1086/422329. View

19.

Barbosa V, da Silva N, Martins R . Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies. Braz J Med Biol Res. 2005; 38(5):801-5. DOI: 10.1590/s0100-879x2005000500020. View

20.

Cansu D, Kalifoglu T, Korkmaz C . Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol. 2008; 35(3):421-4. View